Sound Bioventures

Sound Bioventures, founded in 2022 and based in Malmo, Sweden, is a venture capital investment firm that focuses on the healthcare and life sciences sectors. The firm targets seed-stage, early-stage, and later-stage companies, particularly those with clinical or near-clinical assets. Sound Bioventures employs a strategy of investing in therapeutic areas without specific focus, aiming to capitalize on positive clinical outcomes. The firm conducts thorough scientific diligence on potential investments and is capable of leading, co-leading, or participating in syndicated deals. It typically holds investments for a period of three to six years, reflecting its commitment to fostering the growth of innovative healthcare solutions.

Philip Brainin

Associate

Casper Breum

Co-Founder and Managing Partner

Johan Kördel Ph.D

Co-Founder and Managing Partner

Bibhash Mukhopadhyay

Managing Partner

Ester Sklarsky

Principal

Thomas Tan Ph.D

Principal

9 past transactions

AnaCardio

Series A in 2025
AnaCardio is a clinical stage biopharmaceutical company focused on developing innovative drugs for the treatment of heart failure. The company's therapeutics aim to enhance the contractility of the heart muscle through a unique mechanism that utilizes a therapeutic peptide. This approach is designed to avoid common adverse effects associated with traditional treatments, such as tachycardia, arrhythmia, ischemia, or hypotension. By improving cardiac output safely, AnaCardio's drugs have the potential to enhance organ function, elevate quality of life, increase functional capacity, and lower the risks of hospitalization and mortality for patients suffering from heart failure.

Artax BioPharma

Convertible Note in 2024
Artax BioPharma is a biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. Its flagship product, AX-024, is an oral small-molecule that selectively targets T-cell activation to treat conditions like asthma, rheumatoid arthritis, psoriasis, and multiple sclerosis. Incorporated in 2013, the company is headquartered in Cambridge, Massachusetts.

Theolytics

Venture Round in 2024
Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

AbolerIS Pharma

Series A in 2023
AbolerIS Pharma is a biotechnology company based in Nantes, France, specializing in the development of immune-modulators aimed at treating transplant rejection, graft-versus-host disease, and autoimmune diseases. Incorporated in 2019, the company offers innovative products such as Anti-CD45RC, a monoclonal antibody designed to deplete effector T cells, and IL-34, a cytokine that promotes the induction of tolerogenic macrophages and regulatory T cells. AbolerIS Pharma employs a unique therapeutic approach that fosters immune tolerance while preserving beneficial immune responses in the context of inflammatory, autoimmune, and degenerative diseases. This strategy allows the company to focus on advancing novel drugs to address significant unmet medical needs in these therapeutic areas.

VarmX

Series B in 2023
VarmX is a pharmaceutical spin-off from the Leiden University Medical Center, focused on the development and manufacturing of therapeutic proteins aimed at restoring blood clotting in patients experiencing bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X that can promptly reinstate blood clotting in patients using direct factor Xa anticoagulants, such as rivaroxaban, apixaban, and edoxaban. These anticoagulants, commonly prescribed for the prevention and treatment of thrombosis and stroke, often lead to severe bleeding as a side effect. PseudoXa addresses this critical issue by effectively stopping and preventing bleeding, thereby enhancing the safety of anticoagulant therapy for millions of patients worldwide.

Arthex Biotech

Series B in 2023
Founded in 2019, Arthex Biotech is a Spanish biotechnology company specializing in the development of antisense RNA therapies for genetic diseases. The company, spun off from the University of Valencia, leverages its team's expertise in drug discovery and microRNAs to create innovative treatments.

Teitur Trophics

Series A in 2023
Teitur Trophics is a biotech company established in 2020 and based in Aarhus, Denmark. The company specializes in the development of circular peptides aimed at addressing neurodegenerative diseases. Its research focuses on small peptides that interact with receptors central to neural function. By gaining insights into the biology of these receptors, Teitur Trophics aims to modulate key mechanisms in neural function, which may facilitate the creation of innovative treatments. These treatments are designed to be administered through daily injections, with the potential to prevent the onset of neurodegenerative conditions.

Breye Therapeutics

Seed Round in 2022
Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.

Artax BioPharma

Venture Round in 2022
Artax BioPharma is a biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. Its flagship product, AX-024, is an oral small-molecule that selectively targets T-cell activation to treat conditions like asthma, rheumatoid arthritis, psoriasis, and multiple sclerosis. Incorporated in 2013, the company is headquartered in Cambridge, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.